Delayed onset of a second paraneoplastic neurological syndrome in eight patients

Background The occurrence of a second delayed paraneoplastic neurological syndrome (PNS), different from the first, in the same patient, is not well known. However, recognition of this possibility is important in the management of the patient with PNS. Objective To describe eight patients who presented with two different PNS with a time delay of months to years. Design, setting and patients Retrospective analysis of eight patients, included in the European PNS database, with two different PNS that occurred months to years apart. Results The median delay between the two different PNS was 15 months. The antibody repertoire did not change between the two episodes. Anti-Hu was detected in five patients, and anti-CV2 and anti-Ri in one each. One patient did not present onconeural antibodies. Lung cancer was diagnosed in six patients. In five patients, the second PNS revealed a cancer relapse (n=4) or a second cancer (n=1) and in three it occurred without evidence of tumour recurrence. In these three patients, all with anti-Hu antibodies, the second episode consisted of a lower motor neuron disease. Median survival was not reached after a median follow-up of 5 years. Conclusions A second PNS can reveal a cancer relapse but can also arise in its absence. The long survival of patients with a second PNS suggests that the immune response might be more effective in controlling the cancer.

[1]  J. Honnorat,et al.  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. , 2010, Archives of neurology.

[2]  J. Honnorat,et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  C. Elger,et al.  Neurological course of long-term surviving patients with SCLC and anti-Hu syndrome , 2007, Journal of the Neurological Sciences.

[4]  J. Delattre,et al.  Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes , 2004, Neurology.

[5]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[6]  T. Chuma,et al.  Anti‐Hu paraneoplastic syndrome presenting with brainstem‐cerebellar symptoms and Lambert–Eaton myasthenic syndrome , 2003, Neuropathology : official journal of the Japanese Society of Neuropathology.

[7]  S. Gill,et al.  Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer , 2003, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  C. Adler,et al.  Paraneoplastic chorea associated with CRMP‐5 neuronal antibody and lung carcinoma , 2002, Annals of neurology.

[9]  G. Escaramís,et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. , 2001, Brain : a journal of neurology.

[10]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[11]  Adriano Chiò,et al.  Patients with amyotrophic lateral sclerosis and cancer do not differ clinically from patients with sporadic amyotrophic lateral sclerosis , 2000, Journal of Neurology.

[12]  W. Mason,et al.  Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. , 1997, Brain : a journal of neurology.

[13]  M. Rosenblum,et al.  Motor neuron syndromes in cancer patients , 1997, Annals of neurology.

[14]  C. Petito,et al.  Motor neuron disease: A paraneoplastic process associated with anti‐Hu antibody and small‐cell lung carcinoma , 1996, Annals of neurology.

[15]  G. Tremblay Neuropathology , 1935, Neurology.